[LUO, Yongzhang 罗永章, LUO, Yongzhang 罗永章, WANG, Hui 王慧, LUO, Yongzhang 罗永章, WANG, Hui 王慧, LI, Hui 李辉, LUO, Yongzhang 罗永章, WANG, Hui 王慧, LI, Hui 李辉, LU, Xinan 鲁薪安, LUO, Yongzhang 罗永章, WANG, Hui 王慧, LI, Hui 李辉, LU, Xinan 鲁薪安, FU, Yan 付彦, LUO, Yongzhang 罗永章, WANG, Hui 王慧, LI, Hui 李辉, LU, Xinan 鲁薪安, FU, Yan 付彦, ZHAN, Shunli 占顺利, LUO, Yongzhang 罗永章, WANG, Hui 王慧, LI, Hui 李辉, LU, Xinan 鲁薪安, FU, Yan 付彦, ZHAN, Shunli 占顺利, ZHOU, Daifu 周代福] No. 1, Tsinghua Yuan, Haidian District 中国北京市海淀区清华园1号, Beijing 100084Beijing 100084;B412, 5 Kaituo Road, Haidian District 中国北京市海淀区开拓路5号B412, Beijing 100085Beijing 100085 Provided in the present invention is a use of endostatin or a functional variant thereof in the preparation of a drug for treating alimentary obesity, non-alcoholic fatty liver disease, insulin resistance or glucose intolerance. In an embodiment of the invention, the functional variant can be YH-16, mES, mYH-16, m003, m007, mZ101, etc.

[ZHANG, Bo 张波, LIU, Junsheng 刘俊生, ZHAN, Shunli 占顺利] Room 305-64075, Enterprise Service Center, Zhoushan Port Comprehensive Bonded Zone, Beichan Township (Comprehensive Bonded Zone), Dinghai District 中国浙江省舟山市定海区北禅乡（综保区）舟山港综合保税区企业服务中心305-64075室, Zhejiang 316013Zhoushan, Zhejiang 316013 Provided is a method for constructing an saRNA microvesicle delivery system, comprising the following steps: (1) designing an saRNA expression vector 1 and a membrane protein expression vector 2; and (2) co-transfecting the expression vector 1 and the expression vector 2 into a host cell; and (3) culturing the host cell, and isolating microvesicles containing an saRNA, the saRNA containing a target gene sequence, a replicon in the saRNA expression vector being an alphavirus replicon, and the microvesicles not containing capsid protein. The system can efficiently deliver the saRNA to cells or in vivo so as to realize the expression of a target protein. On this basis, different elements in the delivery system can be further transformed so as to develop a high-efficiency low-immunogenicity modular platform aiming at different diseases and different targets. The delivery system may supplement the toolbox of existing viral and lipid nanoparticle delivery vectors and has good application prospects.

[ZHANG, Bo 张波, YE, Hanqing 叶寒青, ZHANG, Yanan 张亚南, LI, Na 李娜, ZHANG, Qiuyan 张秋艳, DENG, Chenglin 邓成林, YUAN, Shaopeng 袁绍鹏, ZHAN, Shunli 占顺利, GAO, Lei 高磊] Room 289, 4th Floor, No. 2, Wanshou Road West Street, Haidian District 中国北京市海淀区万寿路西街2号四层289室, Beijing 100036Beijing 100036 Provided are an attenuated virus of a flavivirus virus and the use thereof. The attenuated virus comprises a polyadenylic acid (poly(A)) sequence, wherein the polyadenylic acid (poly(A)) is used for replacing a part of the nucleotide sequence of a 3' untranslated region (3'UTR) of the flavivirus virus, so that the 3' untranslated region (3'UTR) of the attenuated virus obtained after the part of the nucleotide sequence of the flavivirus virus is replaced at least retains a 3'-end stem loop region (3'SL). The attenuated virus can be used for preparing safe and effective attenuated vaccine strains.